Медицинский Совет

Расширенный поиск

Моксифлоксацин: фокус на профиль безопасности

Полный текст:


Сегодня новые, или так называемые респираторные, фторхинолоны относятся к одной из групп антимикробных препаратов (АМП), наиболее часто назначаемых по такому актуальному в повседневной клинической практике показанию, как внебольничные инфекции нижних дыхательных путей (вИНДП).

Об авторе

А. И. Синопальников
Российская медицинская академия последипломного образования, Москва

Список литературы

1. Owens R., Ambrose P. Clinical use of the fluoroquinolones // Med. Clin. North. Am. 2000. №84. P. 1447–1469.

2. Bolon M.K. The newer fluoroquinolons // Med. Clin. North. Amer. 2011. №95. P. 793–817.

3. Ball P. The quinolones: history and overview. In: Andriole VT, editor. The quinolones. Third edition. San Diego //

4. Academic Press. 2000. P. 1–33.

5. O’Donnell J.A., Gelone S.P. The newer fluoroquinolones // Infect. Dis. Clin. North. Amer. 2004. №18. P. 691–716.

6. Yuan X., Liang B.-B., Wang R. et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials // J. Chemother. 2012. №24. P. 257–267.

7. Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults // Clin. Infect. Dis. 2007. №44

8. (Suppl. 2). P. 27–72.

9. Woodhead M., Blasi F., Ewig S. and the ERS/ESCMID. Task Force. Guidelines for the management of adult lower respiratory tract infections // Clin. Microbiol. Infect. 2011. №17. P. 1–59.

10. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и соавт. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике // Клин. микробиол. и антимикроб. химиотер. 2010.№12(3). P. 186–226.

11. Andriole V.T. The quinolones: past, present, and future // Clin. Infect. Dis. 2005. №41 (Suppl. 2). P. 113–119.

12. Ball P. Adverse drug reactions: Implications for the fluoroquinolones // J. Antimicrob. Chemother. 2003. №51 (Suppl.1). P. 21–27.

13. Drugs@FDA page. Available at: http// Accessed April 18,2011.

14. Available at: http//

15. Kubin R., Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. 41st ICAAC, Sept. 2000, Toronto. Canada, Abst. 820.

16. Ball A.P. The Quinolones – history and overview. In: The Quinolones, 3rd Edition. Ed VT Andriole. San Diego, USA. Academic Press, 2001. Chap.1.

17. Ball P., Stahlmann R., Kubin R. et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies // Clin. Ther. 2004. №26. P. 940–950.

18. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of safety profile of oral moxofloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28: 443-452.

19. Iannini PB, Kubin R, Reiter C. Over 10 million patient uses: an update on the safety profile of oral moxifloxacin.

20. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, USA(2002) (Poster L-374).

21. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. An analysis of 14 years of clinical data. Drugs R D 2012; 12: 71-100.

22. Owens RC, Ambrose PG. Atnimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 2): S144- S157.

23. Avelox® 400 mg film-coated tablets. Summary of product characteristics. Bayer Healthcare Pharmaceuticals Inc.,Leverkusen, Germany, Revised March 2008

24. Veyssier P, Voirot P, Begaud B, et al. Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study)[in French]. Med Mal Infect 2006; 36: 505-512.

25. US Avelox® package insert [online]. Available from URL: [Accessed 2009 March 18].

26. Haverkamp W, Kruesmann F, Fritsch A, et al. Update on the cardiac safety of moxifloxacin. Current Drug Safety 2012; 7: 149-163.

27. Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organization. Drug Saf 2007; 30: 705-713.

28. Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antomicrob Agents Chemother 2006; 50: 3216-3219.

29. EMEA. Annex II. The scientific conclusions and the grounds for amendments of the summary of product characteristics and package leaflet. December 2008. register/refh_others.htm

30. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.

31. Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007; 60: 121-126.

32. van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359-378.

Просмотров: 71

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)